Generation and characterization of protective antibodies to Marburg virus

mAbs

Volumn 9, Issue 4, 2017, Pages 696-703

  Froude, Jeffrey W ^a,g   Pelat, Thibaut ^b,c   Miethe, Sebastian ^d,e   Zak, Samantha E ^a   Wec, Anna Z ^f   Chandran, Kartik ^f   Brannan, Jennifer Mary ^a   Bakken, Russell R ^a   Hust, Michael ^d   Thullier, Philippe ^b   Dye, John M ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b INSTITUT DE RECHERCHE BIOMÉDICALE DES ARMÉES   (France)

^c BIOTEM   (France)

^d TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

^e YUMAB GmbH   (Germany)

^f ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^g Department of Experimental Therapeutics at Walter Reed Army Medical Research Institute ^*  (United States)

Author keywords

Antibody; biodefense; ebola; filovirus; hemorrhagic; Marburg; murine; protection; therapeutic

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; NEUTRALIZING ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ARTICLE; BONE MARROW; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE LIBRARY; GENE SEQUENCE; HUMAN; HUMAN CELL; IMMUNIZATION; MACACA; MALE; MARBURGVIRUS; MARBURGVIRUS INFECTION; MOUSE; NONHUMAN; PHAGE DISPLAY; SERODIAGNOSIS; VIRUS INFECTION; WESTERN BLOTTING; ANIMAL; ANTIBODY SPECIFICITY; IMMUNOLOGY; MACACA FASCICULARIS;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; HUMANS; MACACA FASCICULARIS; MARBURGVIRUS; SINGLE-CHAIN ANTIBODIES;

EID: 85017167585     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2017.1299848     Document Type: Article

References (37)

1. Kuhn RJ. Togaviridae:The Viruses and Their Replication. In:Knipe DM, Howley PM, eds. Fields Virology. 5 ed. Philadelphia:Lippincott Williams & Wilkins; 2007:1001–22
2. MacNeil A, Rollin PE. Ebola and Marburg hemorrhagic fevers:neglected tropical diseases? PLoS Neglected Trop Dis 2012; 6(6):e1546; PMID:22761967; http://dx.doi.org/10.1371/journal.pntd.0001546
3. Martini G, Siegert R. Marburg Virus Disease. In:Martini GA, GSiegert R, editors. Marburg virus disease–Congresses Springer-Verlag; 1971. p. 250; http://dx.doi.org/10.1007/978-3-662-01593-3
4. Edwards T, Semple MG, De Weggheleire A, Claeys Y, De Crop M, Menten J, Ravinetto R, Temmerman S, Lynen L, Bah EI, et al. Design and analysis considerations in the Ebola_Tx trial evaluating convalescent plasma in the treatment of Ebola virus disease in Guinea during the 2014-2015 outbreak. Clin Trials 2016; 13(1):13–21; PMID:26768570; http://dx.doi.org/10.1177/1740774515621056
5. Froude JW, Stiles B, Pelat T, Thullier P. Antibodies for biodefense. Mabs 2011; 3(6):517–27; PMID:22123065; http://dx.doi.org/10.4161/mabs.3.6.17621
6. Bradfute SB, Dye JM, Jr, Bavari S. Filovirus vaccines. Hum Vaccin 2011; 7(6):701–11; PMID:21519188; http://dx.doi.org/10.4161/hv.7.6.15398
7. Marzi A, Feldmann H. Ebola virus vaccines:an overview of current approaches. Exp Rev Vaccin 2014; 13(4):521–31; PMID:24575870; http://dx.doi.org/10.1586/14760584.2014.885841
8. Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, Carroll MW, Dean NE, Diatta I, Doumbia M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease:final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet 2017; 389(10068):505–18; PMID:28017403; http://dx.doi.org/10.1016/S0140-6736(16)32621-6
9. Geisbert TW, Pushko P, Anderson K, Smith J, Davis KJ, Jahrling PB. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg Infect Dis 2002; 8(5):503–7; PMID:11996686; http://dx.doi.org/10.3201/eid0805.010284
10. Lupton HW, Lambert RD, Bumgardner DL, Moe JB, Eddy GA. Inactivated vaccine for Ebola virus efficacious in guineapig model. Lancet 1980; 2(8207):1294–5; PMID:6108462; http://dx.doi.org/10.1016/S0140-6736(80)92352-1
11. Sullivan NJ, Sanchez A, Rollin PE, Yang ZY, Nabel GJ. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000; 408(6812):605–9; PMID:11117750; http://dx.doi.org/10.1038/35046108
12. Swenson DL, Warfield KL, Negley DL, Schmaljohn A, Aman MJ, Bavari S. Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. Vaccine 2005; 23(23):3033–42; PMID:15811650; http://dx.doi.org/10.1016/j.vaccine.2004.11.070
13. Mupapa K, Massamba M, Kibadi K, Kuvula K, Bwaka A, Kipasa M, Colebunders R, Muyembe-Tamfum JJ. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. International Scientific and Technical Committee. J Infect Dis 1999; 179 Suppl 1:S18–23; PMID:9988160; http://dx.doi.org/10.1086/514298
14. Oswald WB, Geisbert TW, Davis KJ, Geisbert JB, Sullivan NJ, Jahrling PB, Parren PW, Burton DR. Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog 2007; 3(1):e9; PMID:17238286; http://dx.doi.org/10.1371/journal.ppat.0030009
15. Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol 2002; 76(12):6408–12; PMID:12021376; http://dx.doi.org/10.1128/JVI.76.12.6408-6412.2002
16. Dye JM, Herbert AS, Kuehne AI, Barth JF, Muhammad MA, Zak SE, Ortiz RA, Prugar LI, Pratt WD. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A 2012; 109(13):5034–9; PMID:22411795; http://dx.doi.org/10.1073/pnas.1200409109
17. Fusco ML, Hashiguchi T, Cassan R, Biggins JE, Murin CD, Warfield KL, Li S, Holtsberg FW, Shulenin S, Vu H, et al. Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs. PLoS Pathog 2015; 11(6):e1005016; PMID:26115029; http://dx.doi.org/10.1371/journal.ppat.1005016
18. Flyak AI, Ilinykh PA, Murin CD, Garron T, Shen X, Fusco ML, Hashiguchi T, Bornholdt ZA, Slaughter JC, Sapparapu G, et al. Mechanism of human antibody-mediated neutralization of Marburg virus. Cell 2015; 160(5):893–903; PMID:25723164; http://dx.doi.org/10.1016/j.cell.2015.01.031
19. Kajihara M, Marzi A, Nakayama E, Noda T, Kuroda M, Manzoor R, Matsuno K, Feldmann H, Yoshida R, Kawaoka Y, et al. Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein. J Virol 2012; 86(24):13467–74; PMID:23035224; http://dx.doi.org/10.1128/JVI.01896-12
20. Warfield KL, Bradfute SB, Wells J, Lofts L, Cooper MT, Alves DA, Reed DK, VanTongeren SA, Mech CA, Bavari S. Development and characterization of a mouse model for Marburg hemorrhagic fever. J Virol 2009; 83(13):6404–15; PMID:19369350; http://dx.doi.org/10.1128/JVI.00126-09
21. Fusco ML, Hashiguchi T, Cassan R, Biggins JE, Murin CD, Warfield KL, Li S, Holtsberg FW, Shulenin S, Vu H, et al. Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs. PLoS Pathog 2015; 11(6):e1005016; PMID:26115029; http://dx.doi.org/10.1371/journal.ppat.1005016
22. Frenzel A, Kugler J, Wilke S, Schirrmann T, Hust M. Construction of human antibody gene libraries and selection of antibodies by phage display. Methods Mol Biol 2014; 1060:215–43; PMID:24037844; http://dx.doi.org/10.1007/978-1-62703-586-6_12
23. Goh KC, Tang CK, Norton DC, Gan ES, Tan HC, Sun B, Syenina A, Yousuf A, Ong XM, Kamaraj US, et al. Molecular determinants of plaque size as an indicator of dengue virus attenuation. Sci Rep 2016; 6:26100; PMID:27185466; http://dx.doi.org/10.1038/srep26100
24. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 2003; 2(1):52–62; PMID:12509759; http://dx.doi.org/10.1038/nrd984
25. Pushko P, Bray M, Ludwig GV, Parker M, Schmaljohn A, Sanchez A, Jahrling PB, Smith JF. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 2000; 19(1):142–53; PMID:10924796; http://dx.doi.org/10.1016/S0264-410X(00)00113-4
26. Hevey M, Negley D, Pushko P, Smith J, Schmaljohn A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. Virology 1998; 251(1):28–37; PMID:9813200; http://dx.doi.org/10.1006/viro.1998.9367
27. Pelat T, Hust M, Hale M, Lefranc MP, Dubel S, Thullier P. Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol 2009; 9:60; PMID:19563687; http://dx.doi.org/10.1186/1472-6750-9-60
28. Rulker T, Voss L, Thullier P, Isolatio O' Brien LM, Pelat T, Perkins SD, Langermann C, Schirrmann T, Dübel S, Marschall HJ, et al. Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo. PloS One 2012; 7(5):e37242; PMID:22666347; http://dx.doi.org/10.1371/journal.pone.0037242
29. Schutte M, Thullier P, Pelat T, Wezler X, Rosenstock P, Hinz D, Kirsch MI, Hasenberg M, Frank R, Schirrmann T, et al. Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus. PloS One 2009; 4(8):e6625; PMID:19675673; http://dx.doi.org/10.1371/journal.pone.0006625
30. Hust M, Meyer T, Voedisch B, Rülker T, Thie H, El-Ghezal A, Kirsch MI, Schütte M, Helmsing S, Meier D, et al. A human scFv antibody generation pipeline for proteome research. J Biotechnol 2011; 152(4):159–70; PMID:20883731; http://dx.doi.org/10.1016/j.jbiotec.2010.09.945
31. Sambrook JDR. Molecular Cloning:A Laboratory Manual, Third Edition Joe Sambrook Publisher:Cold Spring Harbor Laboratory Press, 2001 ISBN 10:0879695773 ISBN 13:9780879695774
32. Rondot S, Koch J, Breitling F, Dubel S. A helper phage to improve single-chain antibody presentation in phage display. Nat Biotechnol 2001; 19(1):75–8; PMID:11135557; http://dx.doi.org/10.1038/83567
33. Soltes G, Hust M, Ng KK, Bansal A, Field J, Stewart DI, Dübel S, Cha S, Wiersma EJ. On the influence of vector design on antibody phage display. J Biotechnol 2007; 127(4):626–37; PMID:16996161; http://dx.doi.org/10.1016/j.jbiotec.2006.08.015
34. Pelat T, Thullier P. Non-human primate immune libraries combined with germline humanization:an (almost) new, and powerful approach for the isolation of therapeutic antibodies. Mabs 2009; 1(4):377–81; PMID:20068407; http://dx.doi.org/10.4161/mabs.1.4.8635
35. Jager V, Bussow K, Wagner A, Weber S, Hust M, Frenzel A, Schirrmann T. High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells. BMC Biotechnol 2013; 13:52; PMID:23802841; http://dx.doi.org/10.1186/1472-6750-13-52
36. Moe JB, Lambert RD, Lupton HW. Plaque assay for Ebola virus. J Clin Microbiol 1981; 13(4):791–3; PMID:7014628
37. Takada A, Robison C, Goto H, Sanchez A, Murti KG, Whitt MA, Kawaoka Y. A system for functional analysis of Ebola virus glycoprotein. Proc Natl Acad Sci U S A 1997; 94(26):14764–9; PMID:9405687; http://dx.doi.org/10.1073/pnas.94.26.14764